Any current/future new fundraising through debt or equity?

There is no mention of any new fundraising through debt or equity in the provided transcript. The company has raised about ₹44 crore through fully convertible warrants issued to non-promoter investors, which will be used for acquiring Infinium Healthcare Private Limited and its USA iodine project. The current net debt is ₹4.8 crore as of March 31, which includes minor working capital and term loans. There are no further term loans outstanding as of now. Capital expenditure is planned and ongoing, funded through internal accruals, warrant money, and minor bank loans, but no new fundraising is i

Any current/future capex/capital investment/strategic investment?

Planned expenditure of approximately Rs. 22 crore for current manufacturing facility expansion; Rs. 15 crore already incurred. Capital expenditure of Rs. 11 crore on contrast media raw materials plant expected to complete by March 31, 2025, contributing ~20% to revenue growth from FY2026. Rs. 40-44 crore investment into Infinium Healthcare Private Limited for iodine extraction JV in the USA (70 crore project total capex) focused on producing 100 metric tons of iodine annually, aiming for commercial production by December 2024. IPO funds (~20-25 crore) mainly used for reducing working cap

Future growth expectations in sales/revenue/volumes?

Target iodine derivatives capacity utilization to increase from 293 metric tons in FY24 to at least 400 metric tons within 1-2 years. Vision 2030 to reach iodine consumption of 800 to 1000 metric tons annually. Contrast media segment expected to contribute approximately 20% to revenue growth by FY26. From year 1 of the contrast media plant, revenue targeted between Rs. 30 to 40 crores, with potential to ramp up further due to demand from Europe and America. Target long-term gross margin expansion to 22-25%, currently around 21-25%, with potential to reach around 30% due to US raw material sour

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects a top-line revenue of over ₹200 crore by FY26. Sustainable profit margin around 10% is projected for FY26. EBITDA margin has nearly doubled over 5 years, standing at 15% for FY24. Strategic expansions into contrast media segment expected to contribute ~20% to revenue growth by FY26. Growth supported by stable raw material supply, backward integration, and new product launches. Marketing efforts and REACH registrations will facilitate European and international market expansion. Expected capacity utilization to increase from 293 metric ton in FY24 to 400 metric ton in next 1-2 y

Current/ Expected Orderbook/ Pending Orders?

As of the latest update, the company served around 274 customers last year, which increased to 332 customers recently, adding about 65 new customers. The orderbook shows strong dependence on the top clients, with the top 10 clients contributing about 61.86% of the revenue. Retention rate for clients is approximately 70%, with around 30% of clients being cyclical or project-specific. The company’s sales volume is linked to pharmaceutical projects, varying as these projects progress from R&D to commercial phases. Growth in order volume is expected with the upscaling of client projects. No exact

Infinium PharmaQ4 FY24Pharmaceuticals & Biotechnology

Infinium Pharma Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹294.9P/E: 37.8Market Cap: ₹460 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Target iodine derivatives capacity utilization to increase from 293 metric tons in FY24 to at least 400 metric tons within 1-2 years.
Vision 2030 to reach iodine consumption of 800 to 1000 metric tons annually.
Contrast media segment expected to contribute approximately 20% to revenue growth by FY26.
From year 1 of the contrast media plant, revenue targeted between Rs. 30 to 40 crores, with potential to ramp up further due to demand from Europe and America.
Target long-term gross margin expansion to 22-25%, currently around 21-25%, with potential to reach around 30% due to US raw material sourcing.
Revenue expected to cross Rs. 200 crore by FY26 with sustainable profit margin around 10%.
Continued expansion into new geographies through REACH registrations and exhibitions, targeting around 16 product REACH registrations by end of 2024 to boost exports.
Customer base growth from 274 to 332, with plans to increase revenue with project upscales.

Margin guidance

Category 1

Company expects a top-line revenue of over ₹200 crore by FY26.
Sustainable profit margin around 10% is projected for FY26.
EBITDA margin has nearly doubled over 5 years, standing at 15% for FY24.
Strategic expansions into contrast media segment expected to contribute ~20% to revenue growth by FY26.
Growth supported by stable raw material supply, backward integration, and new product launches.
Marketing efforts and REACH registrations will facilitate European and international market expansion.
Expected capacity utilization to increase from 293 metric ton in FY24 to 400 metric ton in next 1-2 years.
ROE for JV expected to be better than core company’s ~15%, with payback period around 3.5-4 years.
Margin expansion from 22-25% gross margin to possibly 30% due to US raw material sourcing and contrast media growth.

See what Infinium Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

There is no mention of any new fundraising through debt or equity in the provided transcript.
The company has raised about ₹44 crore through fully convertible warrants issued to non-promoter investors, which will be used for acquiring Infinium Healthcare Private Limited and its USA iodine project.
The current net debt is ₹4.8 crore as of March 31, which includes minor working capital and term loans.
There are no further term loans outstanding as of now.
Capital expenditure is planned and ongoing, funded through internal accruals, warrant money, and minor bank loans, but no new fundraising is indicated beyond this.
The company focuses on using existing funds efficiently for expansions, joint ventures, and acquisitions.

Order book

As of the latest update, the company served around 274 customers last year, which increased to 332 customers recently, adding about 65 new customers.
The orderbook shows strong dependence on the top clients, with the top 10 clients contributing about 61.86% of the revenue.
Retention rate for clients is approximately 70%, with around 30% of clients being cyclical or project-specific.
The company’s sales volume is linked to pharmaceutical projects, varying as these projects progress from R&D to commercial phases.
Growth in order volume is expected with the upscaling of client projects.
No exact value for current or expected orderbook was disclosed, but the expansion into new segments and markets suggests a positive outlook for pending orders.
Commercial production from new projects like the iodine JV is expected to start by December 2024, further boosting order intake.

See what Infinium Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned expenditure of approximately Rs. 22 crore for current manufacturing facility expansion; Rs. 15 crore already incurred.
Capital expenditure of Rs. 11 crore on contrast media raw materials plant expected to complete by March 31, 2025, contributing ~20% to revenue growth from FY2026.
Rs. 40-44 crore investment into Infinium Healthcare Private Limited for iodine extraction JV in the USA (70 crore project total capex) focused on producing 100 metric tons of iodine annually, aiming for commercial production by December 2024.
IPO funds (~20-25 crore) mainly used for reducing working capital and term loan repayment; 5 crore earmarked for contrast media plant completion.
Expansion through JV in USA iodine project; no other major expansions currently planned beyond those mentioned.
Long-term vision includes increasing iodine utilization to 800-1000 metric tons by 2030, supported by strategic investments and marketing activities.

Track Infinium Pharma — get its next earnings analysis in your feed

How does Infinium Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInfinium Pharma

Rev 2Mar 1

See where Infinium Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Infinium Pharma rank in Pharmaceuticals & Biotechnology?

Compare Infinium Pharma against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Infinium Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →